According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI ) / Canonica, Gw; Blasi, F; Paggiaro, P; Senna, G; Passalacqua, G; Spanevello, A; Aliberti, S; Bagnasco, D; Bonavia, M; Bonini, M; Brussino, L; Bucca, C; Caiaffa, Mf; Calabrese, C; Camiciottoli, G; Caminati, M; Carpagnano, Ge; Caruso, C; Centanni, S; Conte, Me; Corsico, Ag; Cosmi, L; Costantino, Mt; Crimi, N; D'Alo, S; D'Amato, M; Giacco, S; Farsi, A; Favero, E; Barbaro, Mpf; Guarnieri, G; Guida, G; Latorre, M; Lo Cicero, S; Lombardi, C; Macchia, L; Mazza, F; Menzella, F; Milanese, M; Montagni, M; Montuschi, P; Nucera, E; Parente, R; Patella, V; Pelaia, G; Pini, L; Puggioni, F; Ricciardi, L; Ricciardolo, Flm; Richeldi, L; Ridolo, E; Rolla, G; Santus, P; Scichilone, N; Spadaro, G; Vianello, A; Viviano, V; Yacoub, M; Zappa, Mc; Heffler, E. - In: THE WORLD ALLERGY ORGANIZATION JOURNAL. - ISSN 1939-4551. - 13:10(2020). [10.1016/j.waojou.2020.100464]

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI )

Blasi F
Secondo
;
Yacoub M;
2020-01-01

Abstract

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.
2020
Severe asthma, Biologics, Oral corticosteroids, Real-life, Registr
File in questo prodotto:
File Dimensione Formato  
Oral CorticoSteroid sparing 2020.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 601.66 kB
Formato Adobe PDF
601.66 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/152058
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 28
social impact